EUROPE PAIN MANAGEMENT DRUGS MARKET FORECAST 2019-2027
Europe Pain Management Drugs Market by Drug Class (Nsaids, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Non-narcotic Analgesics), Market by (Indication, Arthriticpain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-operative Pain, Migraine, Fibromyalgia) & by Geography.
The European market for pain management drugs is a major contributor towards the global pain management drugs market growth due to the presence of a large number of patient population base suffering pain in the region. High demand for pain relievers’ medications in Europe has led to the emergence of numerous drugs manufacturing companies. The Europe market is proliferating at 3.96% CAGR through 2019-2027.
The pain management market of the United Kingdom, Germany, France, Italy, Spain & the collective countries from the Rest of Europe influence the global market growth. The multiple cases of opioid dependence are anticipated to augment the demand for opioid drugs in Germany. However, the rising concern of the opioid epidemic across the world has seriously impacted the growth of opioid drug market in Germany. Due to the moderate death toll in the United Kingdom due to the ineffective dosage of certain pain-relieving medications, their respective dosages are limited to a shorter period. This has lowered the preference of such drugs by the patient. This has augmented the demand for effective pain therapy in the country.
The major market players in Europe are Daiichi Sankyo, Inc., Purdue Pharma L.P., Acura Pharmaceuticals, Inc., Novartis, Egalet Corp., Eli Lilly and Company, Insys Therapeutics, Inc., GlaxoSmithKline, Abbott Laboratories, Hikma Pharmaceuticals PLC, Johnson & Johnson, Lupin Ltd., Pfizer, Inc., Merck & Co., Inc. and Cipher Pharmaceuticals Inc.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- OPIOIDS MARKET HOLDS THE LARGEST MARKET SHARE IN TERMS OF DRUG CLASS
- CANCER PAIN INDICATION IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
- MARKET DYNAMICS
- MARKET SCOPE & DEFINITION
- MARKET DRIVERS
- GROWTH IN THE INCIDENCE AND PREVALENCE OF CHRONIC DISEASES
- THE RISE IN AWARENESS REGARDING THE SIDE-EFFECTS OF PAIN MEDICATION
- RISE IN GERIATRIC POPULATION
- MARKET RESTRAINTS
- ACCESSIBILITY OF ALTERNATIVE THERAPIES
- INCREASE IN DRUG MISTREATMENT
- MARKET OPPORTUNITIES
- TECHNOLOGICAL ADVANCEMENT
- GROWTH POTENTIAL IN UNTAPPED ECONOMIES
- MARKET CHALLENGES
- PATENT EXPIRATION
- MARKET BY DRUG CLASS
- NSAIDS
- ANESTHETICS
- ANTICONVULSANTS
- ANTI-MIGRAINE AGENTS
- ANTIDEPRESSANTS
- OPIOIDS
- NON-NARCOTIC ANALGESICS
- MARKET BY INDICATION
- ARTHRITIC PAIN
- NEUROPATHIC PAIN
- CANCER PAIN
- CHRONIC BACK PAIN
- POST-OPERATIVE PAIN
- MIGRAINE
- FIBROMYALGIA
- KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF COMPETITIVE RIVALRY
- REGULATORY FRAMEWORK
- OPPORTUNITY MATRIX
- VALUE CHAIN ANALYSIS
- VENDOR LANDSCAPE
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHICAL ANALYSIS
- EUROPE
- GERMANY
- FRANCE
- THE UNITED KINGDOM
- ITALY
- SPAIN
- REST OF EUROPE
- EUROPE
- COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- COMPANY PROFILES
- ABBOTT LABORATORIES
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ACURA PHARMACEUTICALS, INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- CIPHER PHARMACEUTICALS INC.
- COMPANY PROFILES
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- DAIICHI SANKYO, INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- EGALET CORP.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- ELI LILLY AND COMPANY
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- GLAXOSMITHKLINE
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- HIKMA PHARMACEUTICALS PLC
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- JOHNSON & JOHNSON
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- LUPIN LTD.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- PFIZER, INC.
- COMPANY PROFILES
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- PURDUE PHARMA L.P.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- MERCK & CO., INC.
- COMPANY PROFILES
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- NOVARTIS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- INSYS THERAPEUTICS, INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- STRATEGIC INITIATIVES
- ABBOTT LABORATORIES
TABLE LIST
TABLE 1 EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 2 EUROPE PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 3 EUROPE NSAIDS MARKET 2019-2027 ($ MILLION)
TABLE 4 EUROPE ANESTHETICS MARKET 2019-2027 ($ MILLION)
TABLE 5 EUROPE ANTICONVULSANTS MARKET 2019-2027 ($ MILLION)
TABLE 6 EUROPE ANTI-MIGRAINE AGENTS MARKET 2019-2027 ($ MILLION)
TABLE 7 EUROPE ANTIDEPRESSANTS MARKET 2019-2027 ($ MILLION)
TABLE 8 EUROPE OPIOIDS MARKET 2019-2027 ($ MILLION)
TABLE 9 EUROPE NON-NARCOTIC ANALGESICS MARKET 2019-2027 ($ MILLION)
TABLE 10 EUROPE PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 11 EUROPE ARTHRITIC PAIN MARKET 2019-2027 ($ MILLION)
TABLE 12 EUROPE NEUROPATHIC PAIN MARKET 2019-2027 ($ MILLION)
TABLE 13 EUROPE CANCER PAIN MARKET 2019-2027 ($ MILLION)
TABLE 14 EUROPE CHRONIC BACK PAIN MARKET 2019-2027 ($ MILLION)
TABLE 15 EUROPE POST-OPERATIVE PAIN MARKET 2019-2027 ($ MILLION)
TABLE 16 EUROPE MIGRAINE MARKET 2019-2027 ($ MILLION)
TABLE 17 EUROPE FIBROMYALGIA MARKET 2019-2027 ($ MILLION)
TABLE 18 EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 19 EUROPE PAIN MANAGEMENT DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 20 GERMANY PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 21 GERMANY PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 22 FRANCE PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 23 FRANCE PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 24 THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 25 THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 26 ITALY PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 27 ITALY PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 28 SPAIN PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 29 SPAIN PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
FIGURE LIST
FIGURE 1 EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 2 EUROPE PAIN MANAGEMENT DRUGS MARKET SHARE BY DRUG CLASS 2018 & 2027 (%)
FIGURE 3 EUROPE PAIN MANAGEMENT DRUGS MARKET BY NSAIDS 2019-2027 ($ MILLION)
FIGURE 4 EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANESTHETICS 2019-2027 ($ MILLION)
FIGURE 5 EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANTICONVULSANTS 2019-2027 ($ MILLION)
FIGURE 6 EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANTI-MIGRAINE AGENTS 2019-2027 ($ MILLION)
FIGURE 7 EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANTIDEPRESSANTS 2019-2027 ($ MILLION)
FIGURE 8 EUROPE PAIN MANAGEMENT DRUGS MARKET BY OPIOIDS 2019-2027 ($ MILLION)
FIGURE 9 EUROPE PAIN MANAGEMENT DRUGS MARKET BY NON-NARCOTIC ANALGESICS 2019-2027 ($ MILLION)
FIGURE 10 EUROPE PAIN MANAGEMENT DRUGS MARKET SHARE BY INDICATION 2018 & 2027 (%)
FIGURE 11 EUROPE PAIN MANAGEMENT DRUGS MARKET BY ARTHRITIC PAIN 2019-2027 ($ MILLION)
FIGURE 12 EUROPE PAIN MANAGEMENT DRUGS MARKET BY NEUROPATHIC PAIN 2019-2027 ($ MILLION)
FIGURE 13 EUROPE PAIN MANAGEMENT DRUGS MARKET BY CANCER PAIN 2019-2027 ($ MILLION)
FIGURE 14 EUROPE PAIN MANAGEMENT DRUGS MARKET BY CHRONIC BACK PAIN 2019-2027 ($ MILLION)
FIGURE 15 EUROPE PAIN MANAGEMENT DRUGS MARKET BY POST-OPERATIVE PAIN 2019-2027 ($ MILLION)
FIGURE 16 EUROPE PAIN MANAGEMENT DRUGS MARKET BY MIGRAINE 2019-2027 ($ MILLION)
FIGURE 17 EUROPE PAIN MANAGEMENT DRUGS MARKET BY FIBROMYALGIA 2019-2027 ($ MILLION)
FIGURE 18 PORTER’S FIVE FORCE MODEL
FIGURE 19 EUROPE PAIN MANAGEMENT DRUGS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 20 GERMANY PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 21 FRANCE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 22 THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 23 ITALY PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 24 SPAIN PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 25 REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 26 PAIN MANAGEMENT MARKET SHARE ANALYSIS 2017 (%)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- GERMANY
- FRANCE
- THE UNITED KINGDOM
- ITALY
- SPAIN
- REST OF EUROPE
- EUROPE
- MARKET BY DRUG CLASS
- NSAIDS
- ANESTHETICS
- ANTICONVULSANTS
- ANTI-MIGRAINE AGENTS
- ANTIDEPRESSANTS
- OPIOIDS
- NON-NARCOTIC ANALGESICS
- MARKET BY INDICATION
- ARTHRITIC PAIN
- NEUROPATHIC PAIN
- CANCER PAIN
- CHRONIC BACK PAIN
- POST-OPERATIVE PAIN
- MIGRAINE
- FIBROMYALGIA
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.